Boehringer Ingelheim International Gmbh

Vitae Pharmaceuticals, Inc.

Hydra Biosciences, Inc.

Niklas Heine

Christian Eickmeier

Klaus Fuchs

Cornelia Dorner-Ciossek

Riccardo Giovannini

Doris Riether

Gerald Juergen Roth

Gerhard Schaenzle

Martin Thomas Fleck

Marco Ferrara

Bernd Nosse

Holger Rosenbrock

Uta Friederike Lessel

Dennis Fiegen

Thomas Fox

Janet Rachel Nicholson

Anton Pekcec

Thierry Bouyssou

Dirk Gottschling

Suresh B Singh

Lawrence Wayne Dillard

Jing Yuan

Yajun Zheng

Zhenrong Xu

Kai Gerlach

Salvacion Cacatian

Lanqi Jia

Shankar Venkatraman

Sandra Handschuh

Stefan Scheuerer

Angel Morales-Ramos

David A Claremon

Katerina Leftheris

Michael Robert Turner

Hidenori Takahashi

Hossein Razavi

Christopher Ronald Sarko

Xinyuan Edward Wu

Annekatrin Charlotte Heimann

Lana Louise Smith Keenan

Michael Dennis Lowe

Simon Surprenant

Stefan Hoerer

Guosheng Wu

Alexander Weber

Zhongren Wu

Brian McKeever

Ulrike Gross

Martin Hendrix

Klaus Klinder

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Christoph Hoenke

Stefan Peters

Joerg Kley

Thorsten Lehmann-Lintz

Achim Sauer

Angela Kay Berry

Matthew Russell Netherton

Yi Zhao

Claudia Heine

Scott Hobson

Peter Wilhelm Haebel

Yuri Bukhtiyarov

Marcus Kostka

Deepak S Lala

Heike Neubauer

Radoslaw Lipinski

Marco Ferrera

Cornelia Dornier-Ciossek

Brian Mckeever

The present invention relates to compounds of formula (I) wherein A, X, R, R, R, Rand Rare as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, such as hypertension, preeclampsia, restenosis, a cardiac or respiratory condition, renal disease, liver disease, muscular dystrophy, fibrotic disorders, pain, ischemia or ischemic reperfusion injury, and cancer.

Inhibitors of TRPC6

The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Rto R, Rto R, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The present invention relates to triazolo pyridines of formula (II) and their use as modulators of #-secretase. In particular, the present invention relates to compounds which interfere with #-secretase and/or its substrate and therefore modulate the formation of A&#x3b2; peptides. Accordingly these compounds can be used for the treatment of A&#x3b2;-related pathologies, e.g. Alzheimer's disease. 

Triazolo pyridines as modulators of gamma-secretase

The present invention relates to novel N-(2,2-difluoroethyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)&#xac;propanyl]arylcarboxamide such as compound  The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides

The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein Rto R, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, R, Rand Rhave meanings given in the description. 

N-[(pyridyloxy)propanyl]benzamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Arand Arhave meanings given in the description. 

N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides

This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, Rand Rhave meanings given in the description.

N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, Rhave meanings given in the description. 

N-[(pyrimidinyloxy)propanyl]benzamides

The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

Inhibitors of beta-secretase

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides

Growing community of inventors

Biberach an der Riss, Germany

Niklas Heine